CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 66 enrolled
Drug / intervention
Resveratrol +1 moredrug
Likely dose
Resveratrol 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02246660
NCT02246660N/ACompleted
CompareCT.gov

RESveratrol To Improve Outcomes in oldeR pEople With PAD (the RESTORE Trial)

Northwestern University·interventional·Posted Sep 23, 2014·Updated Apr 30, 2018

In Brief

A clinical study evaluating Resveratrol and Placebo for Peripheral Arterial Disease. Completed, enrolled 66 participants across 1 site.

Detailed Summary

The RESTORE trial will determine whether resveratrol supplementation can improve walking performance in older people with lower extremity peripheral arterial disease (PAD). Resveratrol, a polyphenol and natural supplement, specifically targets several impairments associated with walking difficulty and mobility loss in people with PAD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Arterial Disease
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 23, 2014
Enrollment StartJan 1, 2015
Primary CompletionJul 1, 2016
Study CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 11.8 years ago

Interventions

Resveratroldrug

The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative. OR The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.

Placebodrug

Placebo will be taken orally for 6 months.